NCT04530136: A trial that was reported late by Pharming Technologies B.V.
This trial has reported, although it was 168 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04530136 |
|---|---|
| Title | Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 30, 2020 |
| Completion date | Sept. 7, 2021 |
| Required reporting date | Sept. 7, 2022, midnight |
| Actual reporting date | Feb. 22, 2023 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 168 |